4 research outputs found
Amiloidosis cardiaca por transtiretina: la gammagrafía mostró el camino
Fundamento y objetivo: La amiloidosis cardiaca es una enfermedad grave producida por el depósito extracelular a nivel cardiaco de diversas sustancias que se identifican con el análisis de una biopsia endomiocárdica, técnica invasiva, poco accesible y de difícil interpretación. Debido a que las diversas entidades suponen diferente evolución, tratamiento y pronóstico, tiene gran relevancia clínica conocer el subtipo de esta patología. El objetivo es presentar diferentes técnicas diagnósticas no invasivas que nos puedan orientar a sospechar la amiloidosis por transtiretina.
Método: Con este caso clínico reflejamos tanto la dificultad para llegar al diagnóstico del subtipo de amiloidosis como la utilidad de las pruebas radiológicas, la gammagrafía y la cardiorresonancia, en el diagnóstico diferencial de amiloidosis cardiaca.
Resultados: El intenso depósito cardiaco de forma biventricular en la gammagrafía cardiaca con 99mTc-DPD como el realce tardío biventricular circunferencial en la cardiorresonancia son herramientas muy útiles para orientar hacia el diagnóstico de la amiloidosis por transtiretina
Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy
Although genotyping allows family screening and influences risk-stratification in patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic dysfunction (LVSD), its result is negative in a significant number of patients, limiting its widespread adoption. This study sought to develop and externally validate a score that predicts the probability for a positive genetic test result (G+) in DCM/LVSD. Clinical, electrocardiogram, and echocardiographic variables were collected in 1,015 genotyped patients from Spain with DCM/LVSD. Multivariable logistic regression analysis was used to identify variables independently predicting G+, which were summed to create the Madrid Genotype Score. The external validation sample comprised 1,097 genotyped patients from the Maastricht and Trieste registries. A G+ result was found in 377 (37%) and 289 (26%) patients from the derivation and validation cohorts, respectively. Independent predictors of a G+ result in the derivation cohort were: family history of DCM (OR: 2.29; 95% CI: 1.73-3.04; P < 0.001), low electrocardiogram voltage in peripheral leads (OR: 3.61; 95% CI: 2.38-5.49; P < 0.001), skeletal myopathy (OR: 3.42; 95% CI: 1.60-7.31; P = 0.001), absence of hypertension (OR: 2.28; 95% CI: 1.67-3.13; P < 0.001), and absence of left bundle branch block (OR: 3.58; 95% CI: 2.57-5.01; P < 0.001). A score containing these factors predicted a G+ result, ranging from 3% when all predictors were absent to 79% when ≥4 predictors were present. Internal validation provided a C-statistic of 0.74 (95% CI: 0.71-0.77) and a calibration slope of 0.94 (95% CI: 0.80-1.10). The C-statistic in the external validation cohort was 0.74 (95% CI: 0.71-0.78). The Madrid Genotype Score is an accurate tool to predict a G+ result in DCM/LVSD. (J Am Coll Cardiol 2022;80:1115-1126) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation
Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy
BACKGROUND: Although genotyping allows family screening and influences risk-stratification in patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic dysfunction (LVSD), its result is negative in a significant number of patients, limiting its widespread adoption. OBJECTIVES: This study sought to develop and externally validate a score that predicts the probability for a positive genetic test result (G+) in DCM/LVSD. METHODS: Clinical, electrocardiogram, and echocardiographic variables were collected in 1,015 genotyped patients from Spain with DCM/LVSD. Multivariable logistic regression analysis was used to identify variables independently predicting G+, which were summed to create the Madrid Genotype Score. The external validation sample comprised 1,097 genotyped patients from the Maastricht and Trieste registries. RESULTS: A G+ result was found in 377 (37%) and 289 (26%) patients from the derivation and validation cohorts, respectively. Independent predictors of a G+ result in the derivation cohort were: family history of DCM (OR: 2.29; 95% CI: 1.73-3.04; P < 0.001), low electrocardiogram voltage in peripheral leads (OR: 3.61; 95% CI: 2.38-5.49; P < 0.001), skeletal myopathy (OR: 3.42; 95% CI: 1.60-7.31; P = 0.001), absence of hypertension (OR: 2.28; 95% CI: 1.67-3.13; P < 0.001), and absence of left bundle branch block (OR: 3.58; 95% CI: 2.57-5.01; P < 0.001). A score containing these factors predicted a G+ result, ranging from 3% when all predictors were absent to 79% when ≥4 predictors were present. Internal validation provided a C-statistic of 0.74 (95% CI: 0.71-0.77) and a calibration slope of 0.94 (95% CI: 0.80-1.10). The C-statistic in the external validation cohort was 0.74 (95% CI: 0.71-0.78). CONCLUSIONS: The Madrid Genotype Score is an accurate tool to predict a G+ result in DCM/LVSD